EANS-Adhoc: Intercell AG appoints Staph Leavenworth Bakali as Chief Business Officer - Management Board addition with a successful proven track record in vaccines industry

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

30.09.2010

Vienna (Austria), September 30, 2010 - Intercell AG (VSE: ICLL) today
announced that effective October 1, 2010, Staph Leavenworth Bakali
will join its Management Board as Chief Business Officer with key
responsibilities for the commercial aspects of the Company, directly
leading Marketing and Sales, Corporate and Business Development, and
Alliance Management. Staph will also play a key role with the other
Management Board members in helping drive forward the Company's
strategy. Prior to the appointment to Intercell AG's Management
Board, Staph had stepped down from his position as member of the
Supervisory Board of the Company.

"Staph has an outstanding track record in the vaccines industry and
has made major contributions to the success of some key vaccines
businesses globally. His commercial and strategic experience ideally
complement the skills of our current Management Board", said Gerd
Zettlmeissl, Chief Executive Officer of Intercell AG. "We are proud
to have Staph working with us towards the next growth phase of our
Company."

"Having been a member of Intercell's Supervisory Board for almost
five years, I have been impressed with the progress and capabilities
of the Company and its people in creating value through innovation,
industrialization and commercialization", said Staph Bakali. "I am
delighted to join a very dynamic team and look forward to helping
develop the business further."

Staph brings 20 years of vaccine industry experience from his
previous leadership positions. He was recently Chief Executive
Officer of Genocea Biosciences, a Boston (U.S.) based innovative
biotech vaccine company, and previously Chief Operating Officer for
ID Biomedical (Vancouver, Canada) and PowderJect (Oxford, UK), which
were acquired by GlaxoSmithKline and Chiron, respectively. Staph
Bakali was also previously head of Sales and Marketing for Chiron's
global vaccine business and SmithKline Beecham's Vaccine Business
Unit in France. Staph holds a Masters degree in Management from the
London Business School.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Vice President, Global Head Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market